Tag: Cann Group
Cann Group expects record revenue growth of 111% in FY23
Pharmaceutical company Cann Group Limited announced its FY23 unaudited results, with its operating revenue expected to be approximately $13.5 million, representing growth of 111 per cent or 2.1 times compared to the prior year revenue.
Cann Group names Peter Koetsier as new CEO
Cann Group, a leading manufacturer and supplier of innovative cannabis medicines, appointed Peter Koetsier as its new chief executive officer, effective 16 January 2023.
Cann Group to reinvest $4.3m R&D tax incentive rebate
Cann Group has received a $4.3 million Research and Development Tax Incentive Rebate for fiscal year 2022
Cann Group wraps up acquisition of Satipharm
Cann Group Limited (ASX: CAN) has completed the acquisition of the Satipharm business from Harvest One Cannabis Inc. for CAD$4 million, including conditional deferred...
CSIRO now set to develop new medicinal cannabis products
CSIRO will work hand-in-hand with local manufacturers to develop new medicinal cannabis therapeutics – a move that will also make room in the local...
Cann Group moves to acquire Satipharm with Share Sale Agreement
The acquisition will fast-track the development of medicinal cannabis delivery systems and formulations to be sold over-the-counter across Australia.
Cann Group Limited (ASX:CAN) has signed...
Cann Group falls victim to cyber attack
Medicinal cannabis manufacturer Cann Group announced it has lost $3.6 million in a “sophisticated” cyber-security incident involving an unknown third party.
Cann Group said the...
Cann Group receives $3.2M R&D refund for cannabis med manufacture
Medicinal cannabis supplier and manufacturer Cann Group Limited (ASX:CAN) received today a research and development (R&D) tax incentive refund amounting to $3.2 million.
The Australian...
Cann granted manufacturing licences for its Melbourne facilities
The Federal Department of Health’s Office of Drug Control (ODC) yesterday approved manufacturing licences for Cann Group’s existing Northern and Southern medicinal cannabis facilities...
Cann Group inks broad R&D agreement with CSIRO
Listed medicinal cannabis company Cann Group has inked a broad, multiyear agreement with CSIRO that extends the research and development collaboration between the two parties.
The...
Featured Article
The future of sports manufacturing: Inside M2M Group’s AI-powered strategy
As the sports manufacturing industry evolves, artificial intelligence (AI) is emerging as a critical catalyst for innovation and efficiency.
